- Home
- MNPR vs NYXH Comparison
MNPR vs NYXH Comparison
Compare MNPR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- NYXH
- Stock Information
- Founded
- MNPR 2014
- NYXH 2009
- Country
- MNPR United States
- NYXH Belgium
- Employees
- MNPR N/A
- NYXH N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- MNPR Health Care
- NYXH Health Care
- Exchange
- MNPR Nasdaq
- NYXH Nasdaq
- Market Cap
- MNPR 209.3M
- NYXH 222.3M
- IPO Year
- MNPR 2019
- NYXH 2021
- Fundamental
- Price
- MNPR $35.17
- NYXH $7.47
- Analyst Decision
- MNPR Strong Buy
- NYXH Strong Buy
- Analyst Count
- MNPR 6
- NYXH 4
- Target Price
- MNPR $59.60
- NYXH $14.50
- AVG Volume (30 Days)
- MNPR 55.8K
- NYXH 44.7K
- Earning Date
- MNPR 08-08-2025
- NYXH 08-05-2025
- Dividend Yield
- MNPR N/A
- NYXH N/A
- EPS Growth
- MNPR N/A
- NYXH N/A
- EPS
- MNPR N/A
- NYXH N/A
- Revenue
- MNPR N/A
- NYXH $4,716,818.00
- Revenue This Year
- MNPR N/A
- NYXH $323.07
- Revenue Next Year
- MNPR N/A
- NYXH $204.30
- P/E Ratio
- MNPR N/A
- NYXH N/A
- Revenue Growth
- MNPR N/A
- NYXH N/A
- 52 Week Low
- MNPR $1.72
- NYXH $5.55
- 52 Week High
- MNPR $54.30
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- MNPR 51.51
- NYXH 45.56
- Support Level
- MNPR $31.17
- NYXH $7.56
- Resistance Level
- MNPR $35.01
- NYXH $8.02
- Average True Range (ATR)
- MNPR 2.10
- NYXH 0.23
- MACD
- MNPR 0.11
- NYXH -0.06
- Stochastic Oscillator
- MNPR 46.49
- NYXH 0.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.